Abbott Laboratories

The filing excerpt shows core businesses strengthening, but reported earnings, debt presentation and the pending acquisition deserve a closer read. Operating cash flow was $9.57 billion in 2025 against $8.56 billion in 2024. The ratio of operating cash flow to net income is 1.47, meaning cash generation ran ahead of accounting profit this year, which is a plain check on whether earnings turn into cash. The Beneish M-Score is -2.508, below the -1.78 threshold, and its code-assigned label is not in the elevated manipulation-risk zone. This model compares many ratios between years to screen for patterns associated with earnings manipulation. A score below -1.78 is not flagged, though it is a screen, not an audit conclusion. The Altman Z″-Score is 4.80, in the safe zone of 2.60 or above. This model estimates bankruptcy risk for non-financial firms, and this score suggests low distress risk. The Piotroski F-Score and Fog Index are not on file, so they are not assessed here. Long-term debt figures also differ: the XBRL data shows $9.9 billion for 2025, while the MD&A cites $12.9 billion, so readers may want to confirm which measure they are comparing. Rebates are another area to watch. Rebates and chargebacks were $4.8 billion, or 21.1 percent of gross sales, in 2025, and a one-percentage-point increase would reduce net sales by about $225 million. Readers may also want to look at the Diagnostics and Nutritional Products segments, where COVID-19 declines and lower U.S. volumes are visible, alongside the financing for the Exact Sciences acquisition.

Catalyst.Medical Devices is the main driver. Its sales grew 11.9 percent excluding foreign exchange in 2025, led by Diabetes Care, where continuous glucose monitoring sales reached $7.6 billion in 2025 versus $6.4 billion in 2024. Management also cites FDA approval of the Volt PFA System and the Tendyne TMVR system. Consolidated operating margin rose to 18.2 percent in 2025 from 16.3 percent in 2024, and Medical Devices operating margin reached 33.7 percent. Offsetting this, Diagnostics sales fell 4.5 percent excluding foreign exchange as COVID-19 testing sales dropped to $297 million from $747 million.

Hidden risk.The largest tension is between reported profit and the pending deal. Net income was $6.52 billion in 2025, down from $13.4 billion in 2024, even though operating income rose to $8.05 billion. The excerpt provided does not explain that gap, so readers may want to look at the income statement and notes. On November 19, 2025, Abbott agreed to acquire Exact Sciences for $105 per share in cash, about $21 billion in equity value and $23 billion in enterprise value, and obtained a bridge facility of up to $20.0 billion. Year-end cash and short-term investments were $8.9 billion. Closing depends on Exact Sciences shareholder approval and regulatory clearances.